Ligand Pharmaceuticals Inc
* Ligand enters into Omniab platform license agreement with Gilead Sciences
* Gilead will be responsible for all costs related to programs
* Ligand is eligible to receive annual platform access payments, milestone payments and royalties Source text for Eikon: Further company coverage: )
No comments:
Post a Comment